Clinical Trial Update: Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and efficacy of IRX4204 for mild-to-moderate plaque psoriasis has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• IRX4204

Snippet

Sponsor: Io Therapeutics | Conditions: Psoriasis, Plaque Type Psorisis | Phase 2 | Status: SUSPENDED